Projeto: POCI-01-0145-FEDER-016385

Designação do projeto:	NETDIAMOND - Novos alvos na insuficiência cardíaca diastólica: das comorbilidades à medicina personalizada
Código do projeto:	POCI-01-0145-FEDER-016385
Objetivo Principal:	Reforçar a investigação, o desenvolvimento tecnológico e a inovação
Região de Intervenção:	Norte
Instituição proponente/ Promotor líder/ Entidade coordenadora:	Faculdade de Medicina da Universidade do Porto
Parceiro(s) / Co-promotor(es) / Instituição(ões) participante(s):	Faculdade de Ciências Médicas; IBMC - Instituto de Biologia Molecular e Celular ; Instituto de Biologia Experimental e Tecnológica; Instituto Nacional de Engenharia Biomédica; IPATIMUP - Instituto de Patologia e Imunologia Molecular da UP; Universidade de Aveiro
Data de aprovação:	2016-09-30
Data de início:	2016-12-01
Data de conclusão:	2021-02-28

Apoio Financeiro Global

União Europeia - FEDER:

578.823,83 EUR

Objetivos, atividades e resultados esperados/atingidos

Objetivos e Atividades
NETDIAMOND joins a network of national centres of reference with complementary expertizes to address this novel and highly relevant issue: to unravel key routes and mechanisms that lead from comorbidities to endothelial dysfunction, disturbed mechanisms of intercellular communication and ultimately to cardiomyocyte dysfunction in HFpEF. Thus NETDIAMOND has the following objectives:
1. implement a national multicentric standard practise of clinical, functional and follow-up data, and myocardial sample collection in HFpEF patients as well as a national registry for HFpEF;
2. examine well-characterized cohorts of HFpEF patients and their blood sample banks by comprehensive high throughput omics approaches, from genome to proteome, and apply omics approaches in paired samples of tissues such as myocardium and adipose tissue from patients with or without certain comorbidities as a step towards precision medicine;

Resultados Esperados/Atingidos
NETDIAMOND's main topic of research, HFpEF, is a major current health issue. The role of underlying comorbidities as drivers of disease progression by way of inflammation and microvascular dysfunction remains undefined. NETDIAMOND addresses this issue with state-of-the-art methodologies and complementary strategies from a discovery science approach based on omics that will identify gene variants that may predispose to disease and gene and protein expression profiles related to each of the major comorbidities. This will enable a systems biology view of HFpEF by advanced mathematical modelling, to a hypothesis-driven research of the mechanisms of disturbed cell communication and cellular dysfunction in endothelial cells, adipocytes, cardiac fibroblasts, inflammatory cells and cardiomyocytes that lead from systemic inflammation to microvascular dysfunction and ultimately cardiomyocyte stiffness. These mechanisms will be investigated by cellular culture and co-culture and in vitro

Recomendar Página Voltar ao Topo

Copyright 1996-2024 © Faculdade de Engenharia da Universidade do Porto I Termos e Condições I Acessibilidade I Índice A-Z I Livro de Visitas
Página gerada em: 2024-05-19 às 09:22:13 | Política de Utilização Aceitável | Política de Proteção de Dados Pessoais | Denúncias